Oncoceutics’ Second Generation Program for ONC201 Receives NIH SBIR Grant For Collaboration with Provid Pharmaceuticals and Pennsylvania State University
Hummelstown, PA (August 8, 2014) – Oncoceutics, Inc., a biotechnology company focused on developing innovative oncology treatments addressing major unmet medical needs to advance cancer care, announced that an NIH SBIR grant (1R43CA177002) has been awarded by the National Cancer Institute to develop second-generation analogs for its lead product, ONC201. The grant will fund research
Business Development